Johnson & Johnson reported 15 positions worth $761.69M for the quarter ended Sep 30, 2026, down 4.6% on the prior quarter. It opened 0 new positions, added to 1, trimmed 0 and exited 0. Its largest holding is Protagonist Therapeutics, Inc at 45.3% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| CBRS Cerebras Systems Inc. | +75.1K | +140.1% | $13.33M | 3% |
No positions were reduced this quarter.
No new positions this quarter.
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | PTGX Protagonist Therapeutics, Inc | Healthcare | 2.45M | $345.07M | 45.3% | 0 | 0.0% | Unchanged | 3.71% |
| 2 | NBTX Nanobiotix S.A. | Healthcare | 5.62M | $175.24M | 23.01% | 0 | 0.0% | Unchanged | 11.76% |
| 3 | MGTX MeiraGTx Holdings plc | Healthcare | 6.64M | $73.05M | 9.59% | 0 | 0.0% | Unchanged | 7.05% |
| 4 | RAPP Rapport Therapeutics, Inc. | Healthcare | 1.78M | $59.96M | 7.87% | 0 | 0.0% | Unchanged | 3.72% |
| 5 | CTNM Contineum Therapeutics, Inc. | Healthcare | 1.98M | $26.56M | 3.49% | 0 | 0.0% | Unchanged | 5.26% |
| 6 | CBRS Cerebras Systems Inc. | Technology | 128.6K | $22.85M | 3% | +75.1K | +140.1% | Added | 0.06% |
| 7 | XNCR Xencor Inc | Healthcare | 748.1K | $18.66M | 2.45% | 0 | 0.0% | Unchanged | 0.99% |
| 8 | LEGN Legend Biotech Corp | Healthcare | 814.6K | $16.20M | 2.13% | 0 | 0.0% | Unchanged | 0.44% |
| 9 | FATE Fate Therapeutics Inc | Healthcare | 3.38M | $8.01M | 1.05% | 0 | 0.0% | Unchanged | 2.81% |
| 10 | CVRX CVRx, Inc. | Healthcare | 4.02M | $7.04M | 0.925% | 0 | 0.0% | Unchanged | 15.11% |
| 11 | PRCT PROCEPT BioRobotics Corp | Healthcare | 357.9K | $6.52M | 0.856% | 0 | 0.0% | Unchanged | 0.63% |
| 12 | NMRA Neumora Therapeutics, Inc. | Healthcare | 1.85M | $1.10M | 0.145% | 0 | 0.0% | Unchanged | 0.98% |
| 13 | VOR Vor Biopharma Inc. | Healthcare | 53.7K | $1.03M | 0.135% | 0 | 0.0% | Unchanged | 0.1% |
| 14 | LAB Standard Biotools Inc. | Healthcare | 312.0K | $231.04K | 0.03% | 0 | 0.0% | Unchanged | 0.08% |
| 15 | ACET Adicet Bio, Inc. | Healthcare | 22.8K | $162.64K | 0.021% | 0 | 0.0% | Unchanged | 0.21% |
Tip. Select a row to see that position’s full history at Johnson & Johnson.
As of its Q3 2026 13F filing, Johnson & Johnson’s five largest positions were Protagonist Therapeutics, Inc (PTGX) at 45.3%, Nanobiotix S.A. (NBTX) at 23.0%, MeiraGTx Holdings plc (MGTX) at 9.6%, Rapport Therapeutics, Inc. (RAPP) at 7.9%, Contineum Therapeutics, Inc. (CTNM) at 3.5% of the reported portfolio.
Johnson & Johnson reported a 13F portfolio worth $761.69M across 15 positions for Q3 2026. That is down 4.6% from the previous quarter.
Its largest purchases by value were Cerebras Systems Inc. ($13.33M). It opened 0 new positions.
From the Form 13F-HR reports Johnson & Johnson files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.